论文部分内容阅读
目的:观察瑞巴派特保留灌肠治疗溃疡性结肠炎(UC)的临床疗效及安全性。方法:随机将128例UC患者分成A、B两组,两组均给与奥沙拉嗪常规治疗,A组患者用瑞巴派特保留灌肠,B组用复方锡类散液保留灌肠治疗。结果:A组患者有效率(93.75%)明显高于B组(81.25%)(P<0.05),未见明显不良反应。结论:瑞巴派特保留灌肠能有效保护UC患者结肠黏膜并促进溃疡愈合,不良反应少,联合奥沙拉嗪能有效治疗溃疡性结肠炎。
Objective: To observe the clinical efficacy and safety of rebamipide retention enema in the treatment of ulcerative colitis (UC). Methods: A total of 128 patients with UC were randomly divided into A and B groups. Both groups were treated with olsalazine routinely. The patients in group A were treated with rebamipide and the patients in group B were treated with compound tin-type fluid retention enema. Results: The effective rate (93.75%) in group A was significantly higher than that in group B (81.25%) (P <0.05). No obvious adverse reactions were observed. Conclusion: Rebamipide retention enema can effectively protect the colonic mucosa of UC patients and promote the healing of ulcer with less adverse reactions, and combined with olsalazine can effectively treat ulcerative colitis.